<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129737</url>
  </required_header>
  <id_info>
    <org_study_id>ESREFO 18</org_study_id>
    <nct_id>NCT03129737</nct_id>
  </id_info>
  <brief_title>PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus</brief_title>
  <acronym>PROCIDA</acronym>
  <official_title>Multi-centre Randomised Trial Investigating the Effect of PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus on Tricuspid Regurgitation Progression, Right Ventricular Remodeling and Functional Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ettore Sansavini Health Science Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ettore Sansavini Health Science Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients elected to undergo mitral valve surgery (either repair or replacement) with less
      equal than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (&gt;21mm/m2) at
      preoperative echocardiography will be screened. Consenting patients fulfilling all inclusion
      and exclusion criteria will be included in the study and assigned to elective mitral valve
      replacement or repair with or without concomitant tricuspid annuloplasty in a 1:1 fashion,
      using a blocked randomization scheme balanced within center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed as a prospective, multicentre, multinational, randomized, 2-arm
      parallel group trial. Participating centres are selected based on previous experience with
      the surgical technique and standardised echo imaging. Each center is expected to contribute
      20 to 40 patients over a 12-month enrolment period.

      Patients elected to undergo mitral valve surgery (either repair or replacement) with less
      equal than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (&gt;21mm/m2) at
      preoperative echocardiography will be screened. Consenting patients fulfilling all inclusion
      and exclusion criteria will be included in the study and assigned to elective mitral valve
      replacement or repair with or without concomitant tricuspid annuloplasty in a 1:1 fashion,
      using a blocked randomization scheme balanced within center.

      After discharge patients will be assessed at 1 month (phone contact), 6 month and 1-year
      after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of TR</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of TR at one year follow-up defined as worsening of at least one class with respect to pre-surgery as assessed by the Core lab evaluation of the echocardiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reverse right ventricle (RV) remodelling</measure>
    <time_frame>1 year</time_frame>
    <description>The evaluation of reverse right ventricle (RV) remodelling, assessed as reduction/modification of the end diastolic and end systolic RV diameters with respect to pre-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual TR</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients with moderate to severe TR at one year after surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>NYHA Class</measure>
    <time_frame>1 year</time_frame>
    <description>Modification of NYHA class at one year after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tricuspid (Valve) Insufficiency (Rheumatic)</condition>
  <arm_group>
    <arm_group_label>Tricuspid valve annuloplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (&gt;21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitral valve repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (&gt;21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitral valve surgery</intervention_name>
    <description>Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.</description>
    <arm_group_label>Tricuspid valve annuloplasty</arm_group_label>
    <arm_group_label>Mitral valve repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tricuspid valve annuloplasty</intervention_name>
    <description>Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.</description>
    <arm_group_label>Tricuspid valve annuloplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients undergoing mitral valve surgery (either repair or replacement) with less/equal
        than moderate (≤+2) tricuspid regurgitation and dilated tricuspid annulus (&gt;21mm/m2 BSA) at
        preoperative echocardiography and fulfilling the following selection criteria:

        Inclusion criteria:

          1. Written informed consent

          2. Degenerative mitral valve disease

          3. &gt; 18 years old

        Exclusion Criteria:

        Main exclusion criteria:

          1. Presence of structural or organic tricuspid valve disease

          2. urgent operation

          3. presence of pacemaker leads through the tricuspid annulus

          4. acute endocarditis or other organic valve diseases

          5. previous surgical procedure

          6. Severe TR

          7. Associated cardiac procedure

          8. NYHA class IV

          9. Severe COPD (GOLD class 3,4)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Salomone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione Ettore Sansavini per la Ricerca Scientifica ONLUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khalil Fattouch, MD</last_name>
    <phone>+39 328 8105584</phone>
    <email>khalilfattouch@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Salomone, MD</last_name>
    <phone>+39 389 5635731</phone>
    <email>msalomone@esrefo.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Casa di Cura Montevergine</name>
      <address>
        <city>Mercogliano</city>
        <state>Avellino</state>
        <zip>83013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Zebele, MD</last_name>
    </contact>
    <contact_backup>
      <email>carlo.zebele@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ICLAS</name>
      <address>
        <city>Rapallo</city>
        <state>Genova</state>
        <zip>16035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Martinelli, MD</last_name>
    </contact>
    <contact_backup>
      <email>lumartinelli49@virgilio.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Del Giglio, MD</last_name>
    </contact>
    <contact_backup>
      <email>mdelgiglio@gvmnet.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Anthea Hospital</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Speziale, MD,PhD</last_name>
    </contact>
    <contact_backup>
      <email>gspeziale@gvmnet.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenico Paparella, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <email>domenico.paparella@uniba.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Città di Lecce Hospital</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Gregorini, MD</last_name>
    </contact>
    <contact_backup>
      <email>re.greg@tin.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maria Eleonora Hospital</name>
      <address>
        <city>Palermo</city>
        <zip>90135</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maria Pia Hospital</name>
      <address>
        <city>Torino</city>
        <zip>10132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Comoglio, MD</last_name>
    </contact>
    <contact_backup>
      <email>chiaracomoglio@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

